SUDHIR GUPTA, M.D.; MICHAEL H. GRIECO, M.D., F.A.C.P.; ISRAEL SIEGEL, Ph.D.
Studies of circulating T- and B-lymphocyte rosettes were done in 20 healthy controls and 29 patients with pulmonary tuberculosis, including 18 receiving rifampin chemotherapy. Eight of the 18 patients in the rifampin group (44%) had significant suppression of their T-cell rosettes as compared with patients with tuberculosis not receiving rifampin (P < 0.005). Seven of the eight patients with suppressed T-cell rosettes had received the drug for longer than 6 weeks. No significant difference was observed in circulating T- and B-lymphocyte rosettes between healthy controls and patients not receiving rifampin. Administration of this drug to two healthy subjects in a dosage of 600 mg daily for 28 days was associated with suppression of T-lymphocyte rosettes. The maximum decreases of 40% and 37% were observed at 14 and 21 days respectively, with return to base-line values within 2 weeks of discontinuation of drug therapy; this indicates complete reversibility. Long-term sequential studies will be required to determine whether T-cell suppression after prolonged therapy with rifampin is also reversible or associated with any harmful sequels.
GUPTA S, GRIECO MH, SIEGEL I. Suppression of T-Lymphocyte Rosettes by Rifampin: Studies in Normals and Patients with Tuberculosis. Ann Intern Med. ;82:484–488. doi: 10.7326/0003-4819-82-4-484
Download citation file:
Published: Ann Intern Med. 1975;82(4):484-488.
Infectious Disease, Mycobacterial Infections.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use